Description: Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Home Page: www.pluri-biotech.com
PLUR Technical Analysis
Building No. 5
Haifa,
3508409
Israel
Phone:
972 74 710 8600
Officers
| Name | Title |
|---|---|
| Mr. Yaacov Yanay | President, CEO & Director |
| Ms. Liat Zalts | Chief Financial Officer & Treasurer |
| Mr. Lior Raviv | Chief Technology Officer |
| Dr. Arthur Machlenkin Ph.D. | Chief Scientific Officer |
| Ms. Efrat Livne-Hadass | Chief Wellbeing Officer |
| Ms. Orly Amiran | Chief Quality Officer |
| Ms. Efrat Kaduri | Chief Business Development Officer of Pharma |
| Mr. Nimrod Bar Zvi | Chief Commercial Officer |
| Mr. John Dvor | EVP North America |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 306.5571 |
| Price-to-Sales TTM: | 85.9888 |
| IPO Date: | 2003-06-30 |
| Fiscal Year End: | June |
| Full Time Employees: | 106 |